iRhythm Holdings, Inc. Common Stock
IRTC
$112.88
-5.59%
iRhythm Holdings, Inc. is a digital healthcare company that designs, develops, and commercializes ambulatory cardiac monitoring solutions, primarily through its Zio System—a wearable biosensor patch that continuously records electrocardiogram (ECG) data for up to 14 days, paired with cloud-based analytics software to aid physicians in diagnosing arrhythmias. As a pioneer and leader in the cardiac monitoring space, iRhythm differentiates itself through its FDA-cleared, wire-free patch technology and proprietary AI-driven data analysis, positioning it as a key player in the shift toward remote patient monitoring and preventive cardiology. The current investor narrative centers on the company's robust revenue growth trajectory, recent achievement of GAAP profitability in Q4 2025, and its strategic focus on expanding commercial payer coverage and healthcare institutional adoption, while also navigating competitive pressures and the need to sustain margin improvement. Despite a significant pullback in the stock price over the past year, analysts remain highly optimistic, with a strong buy consensus and substantial upside targets, reflecting confidence in the company's long-term growth potential as it scales its operations.…
IRTC
iRhythm Holdings, Inc. Common Stock
$112.88
Investment Opinion: Should I buy IRTC Today?
Rating: Buy. The thesis is that IRTC is a high-growth digital health leader that has just achieved a profitability inflection, and the stock is undervalued relative to its growth potential, as evidenced by the 43% upside to the average analyst target of $176.14. The Strong Buy consensus and recent upgrade from Evercore ISI reinforce this view.
Sign up to view all
IRTC 12-Month Price Forecast
The AI model assesses IRTC as a bullish opportunity given its strong revenue growth, high gross margins, and recent profitability inflection. The main risks are valuation and competition, but the current price offers a favorable risk/reward. The stance would be upgraded to high confidence if the company delivers another quarter of 25%+ growth and positive EPS, while a downgrade would occur if growth falls below 20% or margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on iRhythm Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $176.14 and implied upside of +56.0% versus the current price.
Average Target
$176.14
0 analysts
Implied Upside
+56.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$157 - $196
Analyst target range
The target price range spans from a low of $157.00 to a high of $196.00, indicating a spread of $39.00, which suggests moderate uncertainty about the stock's future performance. The high target of $196.00 implies a potential upside of 59% from the current price, likely assuming continued strong revenue growth, margin expansion, and successful execution of the company's strategic initiatives. The low target of $157.00 still represents a 28% upside, suggesting that even the most conservative analysts see significant value in the stock. Recent ratings actions have been positive, with firms like Evercore ISI upgrading from 'In Line' to 'Outperform' in January 2026, and no downgrades in the past six months, reinforcing the bullish sentiment.
Bulls vs Bears: IRTC Investment Factors
The bull case is anchored by accelerating revenue growth, a recent GAAP profit, and strong analyst support, while the bear case centers on a rich valuation, high leverage, and a history of underperformance. Currently, the bulls have stronger evidence given the fundamental inflection and the substantial upside to analyst targets, but the key tension is whether the company can sustain its growth and margin expansion to justify the premium multiple. If revenue growth decelerates or margins compress, the stock could face significant de-rating, making the growth-margin tradeoff the most critical factor to watch.
Bullish
- Revenue growth accelerating: Q4 2025 revenue grew 27.1% YoY to $208.9M, up from $164.3M in Q4 2024. Sequential growth from Q1 2025's $158.7M to Q4's $208.9M shows a clear upward trajectory, indicating strong market demand for the Zio System.
- First GAAP profitable quarter: Q4 2025 marked a turning point with net income of $5.6M and EPS of $0.17, versus a net loss of $1.3M in Q4 2024. This achievement of profitability validates the company's path to sustainable earnings and supports the bullish thesis.
- Strong analyst conviction: With a Strong Buy consensus (mean 1.13) from 14 analysts and an average target of $176.14, the stock implies 43% upside from $123.07. The low target of $157 still offers 28% upside, showing even the most bearish analyst sees value.
- High gross margin profile: Gross margin held steady at 70.9% in Q4 2025 (70.9% gross margin ratio), reflecting the software-like economics of the Zio service model. This high margin provides a solid foundation for operating leverage as revenue scales.
Bearish
- Valuation stretched on sales: PS ratio of 7.6 is well above the industry average, pricing in aggressive growth. Even with forward PE of 101, the market expects a massive earnings inflection that may not materialize if growth decelerates.
- Stock down 32% in a year: IRTC has underperformed the S&P 500 by 51 percentage points over the past year (relative strength -51.1%), reflecting investor skepticism about the company's ability to sustain growth and profitability in a competitive market.
- High debt-to-equity ratio: Debt-to-equity of 4.79 indicates significant leverage, which could strain cash flows if interest rates remain elevated or if the company needs to refinance. This financial risk is often overlooked in growth stories.
- Negative operating margin: Despite Q4 profitability, the TTM operating margin is -4.9%, and Q1-Q3 2025 saw operating losses. The company's ability to maintain profitability across all quarters is unproven, and any revenue hiccup could push it back to losses.
IRTC Technical Analysis
iRhythm's stock is currently in a recovery phase after a prolonged downtrend, with the price at $123.07 as of September 4, 2026, reflecting a 32.4% decline over the past year. The stock is trading at approximately 58% of its 52-week range (between $100.85 low and $212.00 high), indicating it has recovered from the lows but remains well below its highs. This positioning suggests that while the stock has stabilized and is attempting to build a base, it has not yet regained the momentum seen in earlier periods, and the current price level may represent a value opportunity if the recovery continues, or a resistance zone if selling pressure persists.
Beta
1.32
1.32x market volatility
Max Drawdown
-46.2%
Largest decline past year
52-Week Range
$101-$212
Price range past year
Annual Return
-38.0%
Cumulative gain past year
| Period | IRTC Return | S&P 500 |
|---|---|---|
| 1m | -7.4% | -1.6% |
| 3m | -0.7% | +2.2% |
| 6m | -0.1% | +14.4% |
| 1y | -38.0% | +16.2% |
| ytd | -35.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IRTC Fundamental Analysis
iRhythm's revenue trajectory is robust, with Q4 2025 revenue reaching $208.9 million, a 27.1% year-over-year increase from $164.3 million in Q4 2024. This growth is driven by strong performance across all segments, with Commercial Payors contributing $111.7 million, Centers for Medicare and Medicaid $49.2 million, and Healthcare Institutions $34.3 million, reflecting broad-based demand for its Zio monitoring system. The multi-quarter trend shows accelerating growth, with revenue rising from $158.7 million in Q1 2025 to $192.9 million in Q3 2025, indicating a consistent upward trajectory that supports the company's expansion strategy.
Quarterly Revenue
$208890000.0B
2025-12
Revenue YoY Growth
+27.1%
YoY Comparison
Gross Margin
70.9%
Latest Quarter
Free Cash Flow
$34521000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IRTC Overvalued?
Given that iRhythm's trailing twelve-month net income is negative (EPS of -$0.0078), the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE ratios are not meaningful for loss-making companies. The current PS ratio stands at 7.60, which is elevated compared to the industry average, reflecting the market's high growth expectations for the company. The forward PE ratio of 101.41 suggests that analysts anticipate a significant earnings inflection, implying that the market is pricing in substantial future profitability, which may be optimistic given the company's current margin profile.
PE
-127.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-1557.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable: despite Q4 2025 profitability, the TTM net margin is -6.0%, and the company has a high debt-to-equity ratio of 4.79, indicating substantial leverage. While free cash flow turned positive at $34.5M TTM, the company's reliance on continued revenue growth to service debt and achieve sustained profitability is a key vulnerability. The negative operating margin of -4.9% TTM suggests that the Q4 profit may be an anomaly, and any cost overruns or revenue shortfalls could quickly erode earnings. Additionally, the high PS ratio of 7.6 means the stock is priced for perfection, leaving little room for error in execution.
FAQ
The key risks are: 1) Financial risk from high debt-to-equity of 4.79 and negative operating margin of -4.9% TTM, which could lead to cash flow issues if growth stalls. 2) Competitive risk from larger players like Philips and BioTelemetry, which could erode market share. 3) Valuation risk from a PS ratio of 7.6, which leaves little room for error. 4) Regulatory risk from potential changes in CMS reimbursement policies. The most severe risk is a combination of growth deceleration and margin compression, which could lead to a 20%+ downside.
The 12-month forecast is bullish, with a base case target of $176 (43% upside) and a bull case target of $196 (59% upside), based on analyst estimates. The bear case target is $100.85 (18% downside), aligning with the 52-week low. The most likely scenario (50% probability) is that the company continues to grow revenue at around 25% and maintains profitability, driving the stock to the average analyst target. The key assumption is that the company can sustain its growth trajectory without major competitive or regulatory setbacks.
IRTC is trading at a PS ratio of 7.6, which is above the industry average, indicating the market is paying a premium for its growth. The forward PE of 101.4 suggests that investors expect significant earnings growth in the near future. Relative to its own history, the stock is well below its 52-week high of $212, but still above its low of $100.85. The valuation implies the market expects the company to sustain 25%+ revenue growth and achieve sustained profitability. If these expectations are met, the stock is fairly valued; if not, it could be overvalued.
IRTC is a good buy for investors with a high risk tolerance and a long-term horizon, given the 43% upside to the average analyst target of $176.14. The company has demonstrated strong revenue growth of 27.1% YoY and achieved its first GAAP profitable quarter, but the stock is volatile and carries significant valuation risk with a PS ratio of 7.6. The biggest downside risk is a growth deceleration or margin compression, which could lead to a de-rating. For those who believe in the long-term adoption of remote cardiac monitoring, the current price offers an attractive entry point.
IRTC is more suitable for long-term investment due to its high growth potential and the expanding market for remote cardiac monitoring. The stock has a beta of 1.32, indicating higher volatility than the market, which makes it less suitable for short-term trading unless one is adept at timing. The company does not pay a dividend, so returns are dependent on capital appreciation. Given the recent profitability inflection and strong revenue growth, a minimum holding period of 3-5 years is recommended to allow the company to scale and realize its full potential.